Previous studies have confirmed that human recombinant fibronectin polypeptide CH50 has the ability to interfere with the expression and activity of integrin αv and β3, resulting in the inhibition of invasive growth of tumor cells and angiogenesis [13], and a 22-mer FN peptide, termed FNIII14, has also been shown to inhibit β1 integrin-mediated adhesion without binding to integrins and has exhibited the potential to prevent lymphoma cell metastasis [14]. Here, FN1 is linked to lymphoma.